US SEC Trading Suspension Halt Orders — June 26, 2026

Regained Nasdaq compliance on June 26, 2026 after closing bid price exceeded $1.00 for 10 consecutive days ending June 25, 2026; delisting risk removed, stock continues trading on Nasdaq Capital Market

Added to Russell Microcap Index effective June 29, 2026, which could trigger forced buying from index funds and ETFs tracking the index, providing temporary price support despite delisting notice

NYSE American accepted compliance plan through October 2, 2027, providing 16 months to fix equity deficiency; stock continues trading normally under MTNB without immediate delisting pressure

Received Nasdaq delisting notice for failing to obtain shareholder approval on $187M in convertible notes; two transactions (SOL: $151.2M at $4.25/share on July 9, 2025, and $36M at $2.39/share on January 9, 2026) could dilute existing shareholders by 20%+

Second NYSE American non-compliance notice in short succession; stockholders' equity of $3.022M as of March 31, 2026 is well below $4.0M threshold, with net losses in 5 of most recent fiscal years

Not eligible for Section 1003(a) exemption despite market cap potentially exceeding $50M, indicating NYSE American views the company as high-risk

Has only until August 10, 2026 to submit compliance plan to Nasdaq; no assurance of acceptance, and failure could lead to Hearings Panel and eventual delisting

Previously faced delisting notice on February 18, 2026 for bid price non-compliance; took over 4 months to resolve, indicating ongoing financial fragility [NEUTRAL/BEARISH]

Convertible note structure at $4.25 and $2.39 per share suggests significant downward pressure on stock price as conversion dilutes equity; current market price likely below these levels

Must submit compliance plan by August 10, 2026 or face immediate delisting proceedings; failure would force stock to OTC markets with severe liquidity loss

Stockholders' equity of $3.022M is 24.5% below the $4.0M threshold; with ongoing losses and no revenue growth mentioned, equity could erode further before October 2027 deadline

Two convertible note issuances totaling $187M could convert into 20%+ of pre-transaction shares; existing shareholders face massive dilution without having voted on the transactions

Second non-compliance notice in short period suggests deteriorating financial condition; if progress under plan is insufficient, NYSE American can initiate delisting without further notice

Failure to obtain shareholder approval for such large transactions raises serious corporate governance red flags; may indicate weak internal controls or management overreach

Regained compliance on bid price but no fundamental improvement disclosed; stock could easily fall below $1.00 again if market conditions worsen, triggering another delisting cycle

All three companies are micro-caps with low liquidity; any delisting event could cause 50-90% price declines as institutional holders are forced to sell

No forward-looking statements about revenue, product approvals, or partnerships in filing; company appears to have no clear path to profitability beyond cost cutting

Addition to Russell Microcap Index on June 29, 2026 creates forced buying from passive funds; could provide 5-15% short-term price appreciation as funds rebalance, despite delisting overhang

Delisting risk fully removed; stock now trades without overhang, potentially attracting new institutional buyers who were previously restricted from holding non-compliant securities

16-month compliance plan through October 2027 provides ample time for turnaround; if company can raise equity or achieve milestone, stock could re-rate significantly from distressed levels

If compliance plan is rejected, company can appeal to Nasdaq Hearings Panel; stay of delisting during appeal process could provide additional months for resolution

Micro-cap biotech and tech companies facing delisting are often acquisition targets at distressed valuations; larger players may see value in distressed assets

From negative (delisting notice) to positive (compliance regained) sentiment shift could drive momentum buying; first positive catalyst in months for the stock

NYSE American's acceptance of compliance plan suggests belief in viability; could indicate hidden value or upcoming catalyst not yet public

If stock trades below conversion prices ($4.25 and $2.39), note holders may be incentivized to support stock price to enable conversion; potential for price floor near conversion levels

2 of 3 filings (Upexi, Matinas) involve active delisting threats, highlighting systemic fragility in micro-cap companies with weak balance sheets and governance issues; both have materiality 9/10, indicating high investor impact

NYSE American and Nasdaq are enforcing listing standards aggressively; Matinas received second non-compliance notice despite having a plan, and Upexi faces delisting for governance failure rather than financial metrics

Both Matinas (16-month plan) and Outlook (4-month recovery) show that exchange compliance plans provide real breathing room; companies with credible plans can avoid immediate delisting and buy time for turnaround

Upexi's simultaneous Russell Microcap Index addition and Nasdaq delisting notice creates a unique arbitrage opportunity; passive funds must buy while active managers may sell, creating potential price dislocations

None of the three filings mentioned revenue growth, margin improvement, or operational catalysts; all focus solely on regulatory compliance, suggesting these companies are in survival mode rather than growth mode

Must submit plan by August 10, 2026; watch for plan details, shareholder vote on convertible notes, and Nasdaq's response. Key date: August 10, 2026

Effective June 29, 2026; monitor trading volume and price action for forced buying from passive funds. Key date: June 29, 2026

Next quarterly filing (likely August 2026) will show if stockholders' equity has improved from $3.022M; any deterioration increases delisting risk

NYSE American will monitor progress under compliance plan; any missed milestones could trigger immediate delisting proceedings

Watch if stock maintains $1.00+ bid price for sustained period; any dip below $1.00 for 30 consecutive days would restart delisting process

No insider transactions reported in these filings; any future insider buying (especially at Upexi and Matinas) would signal management confidence, while selling would be highly bearish

If compliance plan is rejected, company may appeal; watch for hearing dates and outcomes which could extend or terminate listing

With equity at $3.022M and ongoing losses, company likely needs to raise capital; any dilutive offering could further pressure stock price